2024-11-07 - Analysis Report
## Merck & Co., Inc. (MRK) Stock Analysis Report

This report provides a comprehensive analysis of Merck & Co., Inc. (MRK) stock, covering its recent performance, valuation metrics, and market outlook.

### 1. Performance Analysis

Merck & Co., Inc. (MRK) is a leading pharmaceutical company that develops, manufactures, and markets prescription medicines, vaccines, and animal health products. 

**Cumulative Return:**
* MRK: 57.67%
* S&P 500 (VOO): 134.06%

**Performance Gap:**
* **Current Gap:** -76.39%
* **Relative Gap (Percentile):** 9.51%

**Alpha and Beta Analysis:**
| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|------|
| 2015-2017 | -1.6% | 18.1% | -31.8% | 0.9 |
| 2016-2018 | 45.6% | 17.0% | 20.9% | 0.7 |
| 2017-2019 | 51.2% | 17.0% | 8.1% | 0.7 |
| 2018-2020 | 45.5% | 27.2% | 6.4% | 0.7 |
| 2019-2021 | 6.3% | 27.2% | -83.6% | 0.6 |
| 2020-2022 | 26.3% | 27.2% | 8.6% | 0.5 |
| 2021-2023 | 41.1% | 19.8% | 12.3% | 0.3 |
| 2022-2024 | 32.2% | 22.6% | 11.6% | 0.3 |

**Analysis:** MRK has underperformed the S&P 500 significantly over the past few years. It shows negative alpha values for most periods, indicating it has not generated excess returns compared to the benchmark. Beta values suggest a generally lower volatility than the market.

### 2. Recent Price Action

* **Last Price:** 101.21
* **5-Day Moving Average:** 102.51
* **20-Day Moving Average:** 106.46
* **60-Day Moving Average:** 112.22

**Analysis:**  The stock price is currently trading below all three moving averages, indicating a short-term downtrend. 

### 3. Technical Indicators

* **RSI:** 13.67 - This suggests the stock is currently oversold.
* **PPO:** -0.3 - Negative PPO indicates bearish momentum.
* **Delta_Previous_Relative_Divergence (20-day):** -10.76 -  A negative value indicates a short-term downtrend.
* **Expected Return (Long-term, 2+ years):** 0.0% -  Expected return is negligible compared to the S&P 500.

**Analysis:**  Technical indicators are currently showing oversold conditions and bearish momentum. However, the expected return is negligible, indicating a potentially unattractive long-term investment.

### 4. Recent Earnings and Outlook

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | $16.11 B |
| 2024-05-03 | 1.88 | $15.78 B |
| 2023-11-03 | 1.87 | $15.96 B |
| 2023-08-07 | -2.35 | $15.04 B |
| 2024-08-05 | -2.35 | $15.04 B |

**Analysis:**  Merck reported positive earnings in its recent quarter, exceeding analysts' expectations. However, its 2023 Q3 results were impacted by a significant loss. This suggests that despite strong revenue performance, there might be underlying concerns about profitability.  

### 5. Financial Information

**1) Revenue and Profitability:**
   | Quarter | Revenue  | Profit Margin |
   |---|---|---|
   | 2024-06-30 | $16.11B | 76.76% |
   | 2024-03-31 | $15.78B | 77.56% |
   | 2023-12-31 | $14.63B | 73.26% |
   | 2023-09-30 | $15.96B | 73.29% |
   | 2023-06-30 | $15.04B | 73.24% |

**2) Capital and Profitability:**
   | Quarter  | Equity     | ROE |
   |---|---|---|
   | 2024-06-30 | $43.58B  | 12.52% |
   | 2024-03-31 | $40.36B  | 11.80% |
   | 2023-12-31 | $37.58B  | -3.26% |
   | 2023-09-30 | $41.25B  | 11.50% |
   | 2023-06-30 | $38.69B | -15.44% |

**Analysis:**  Merck exhibits strong revenue and profitability, with a consistently high profit margin. However, ROE has fluctuated in recent quarters, potentially indicating challenges in capital efficiency and profitability.

### 6. News and Recent Issues

* **Recent Earnings News:** 
    * You can find the most recent earnings releases and analyst reports on financial news websites like Seeking Alpha, Yahoo Finance, and MarketBeat.
* **Recent Market Outlook:** 
    *  To gain a deeper understanding of current market sentiment, consider analyzing articles on financial news websites like Finbold, Yahoo Finance, and TheStreet. 
* **Analyst Opinions and Performance Highlights:**
    *  Consult analyst ratings and price targets from reputable sources like Wall Street Journal and Bloomberg.


### 7.  Overall Analysis

MRK has underperformed the market significantly in recent years, with a generally low alpha. Despite strong revenue and profitability, recent earnings results suggest potential challenges in profitability and capital efficiency. Technical indicators are currently oversold, with bearish momentum. 

**Overall:** MRK is currently a risky investment. While it may be an oversold stock with potential for a short-term rebound, the long-term expected return is negligible. It is crucial to consider the current market conditions and the potential for a long-term investment strategy before making any decisions.
